Bayer reveals data behind asundexian's stroke win Bayer's oral Factor XIa inhibitor asundexian can reduce the risk of a secondary ischaemic stroke by 26%, according to the OCEANIC-STROKE trial

#Bayer #asundexian #stroke #oralFactorXIainhibitor #FactorXIainhibitor #ischaemicstroke #OCEANICSTROKEstudy #antiplatelettherapy #InternationalStrokeConference #phase3trial #secondarystrokeprevention #anticlottingtherapies #OCEANICSTROKE #acutecoronarysyndromes #preventionofstroke
zurl.co/Mhc1J

¿Un nuevo fármaco frena un 26% la recaída del ictus? Asundexian recorta un 26% la recaída del ictus isquémico: qué mostró OCEANIC-STROKE, quiénes participaron y qué puede cambiar en prevención. El fármaco experimental asundexian ha mostrado una reducció...

¿Un nuevo fármaco frena un 26% la recaída del ictus? #Ictus #IctusIsquemico #AccidenteCerebrovascular #Neurologia #InvestigacionMedica #EnsayoClinico #Salud #Farmacos #Prevencion #TerapiaAntiplaquetaria #Asundexian #OCEANICSTROKE #17defebrero #felizmartes donporque.com/nuevo-farmac...

Myth busted: safer anticoagulants now. Quick win: OCEANIC‑STROKE found asundexian reduced recurrent ischemic stroke ~26% without extra major bleeding in selected patients. Regulators pending. Full breakdown → future.xsbrt.com/FactorXIaStrokePreventio... Save or reply #asundexian

🧐Interesting… #Asundexian was not effective in #AF, but OCEANIC-STROKE shows its superiority when combined with antiplatelet therapy, demonstrating a reduction in ischemic #stroke in patients with non-cardioembolic ischemic stroke or high-risk TIA, compared to placebo plus antiplatelet therapy.
#FXI

#Asundexian εναντίον #Apixaban στην κολπική #μαρμαρυγή

Μεταξύ των ασθενών με κολπική μαρμαρυγή, υπάρχει η ανάγκη για αποτελεσματική #αντιπηκτική #αγωγή που προλαμβάνει το #εγκεφαλικό επεισόδιο, αλλά ενέχει χαμηλότερο κίνδυνο αιμορραγίας από τα του στόματος #αντιπηκτικά άμεσης δράσης. #fibrillation

Asundexian versus Apixaban in Patients with Atrial Fibrillation - PubMed Among patients with atrial fibrillation at risk for stroke, treatment with asundexian at a dose of 50 mg once daily was associated with a higher incidence of stroke or systemic embolism than treatment...

9) Another small molecule, #asundexian, was being studied vs #apixaban for #SPAF in #OCEANIC_AF, but that trial was prematurely terminated due to inferior efficacy of the #FXIa inhibitor. See pubmed.ncbi.nlm.nih.gov/39225267/ & discussion by @CMichaelGibson at cardiometabolic-ce.com/antithrombot....

Uff, das sind wirklich schlechte Nachrichten zu #Asundexian ... absolut keine schöne Zeit, Aktionär von #Bayer zu sein.